Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7622001rdf:typepubmed:Citationlld:pubmed
pubmed-article:7622001lifeskim:mentionsumls-concept:C0020792lld:lifeskim
pubmed-article:7622001lifeskim:mentionsumls-concept:C0021641lld:lifeskim
pubmed-article:7622001lifeskim:mentionsumls-concept:C0441472lld:lifeskim
pubmed-article:7622001lifeskim:mentionsumls-concept:C0022702lld:lifeskim
pubmed-article:7622001lifeskim:mentionsumls-concept:C1261552lld:lifeskim
pubmed-article:7622001lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:7622001pubmed:issue8lld:pubmed
pubmed-article:7622001pubmed:dateCreated1995-8-31lld:pubmed
pubmed-article:7622001pubmed:abstractTextTo examine the kinetic steps in insulin's in vivo action, we have assessed the temporal relationship between arterial insulin, interstitial insulin, glucose disposal rate (GDR), and insulin receptor kinase (IRK) activity in muscle and between portal insulin, hepatic glucose production (HGP), and IRK activity in liver. Interstitial insulin, as measured by lymph-insulin concentration (muscle only), and IRK activity were used as independent methods to determine the arrival of insulin at its tissue site of action. Euglycemic clamps were conducted in seven mongrel dogs and consisted of an activation phase with a venous insulin infusion (7.2 nmol.kg-1.min-1, 100 min) and a deactivation phase. Liver and muscle biopsies were taken to assess IRK activity. Arterial, portal, and lymph insulin rose to 636 +/- 12, 558 +/- 18, and 402 +/- 24 pmol/l, respectively. GDR increased from 13.9 +/- 0.6 to 41.7 +/- 2.8, and HGP declined from 14.4 +/- 0.6 to 1.1 +/- 0.6 mumol.kg-1.min-1. Muscle and liver IRK activity increased significantly from 5.9 +/- 0.9 to 14.6 +/- 0.6 and 5.5 +/- 0.7 to 23.7 +/- 1.9 fmol P/fmol insulin receptor (IR), respectively. The time to half-maximum response (t1/2a) for stimulation of GDR (19.8 +/- 4.8 min) and suppression of HGP (21.5 +/- 3.7 min) were similar. The t1/2a for stimulation of GDR, muscle IRK, and rise in lymph insulin were not significantly different from one another and were all markedly greater than that for the approach to steady state of arterial insulin (2.3 +/- 1.2 min, P < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:7622001pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7622001pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7622001pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7622001pubmed:languageenglld:pubmed
pubmed-article:7622001pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7622001pubmed:citationSubsetAIMlld:pubmed
pubmed-article:7622001pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7622001pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7622001pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7622001pubmed:statusMEDLINElld:pubmed
pubmed-article:7622001pubmed:monthAuglld:pubmed
pubmed-article:7622001pubmed:issn0012-1797lld:pubmed
pubmed-article:7622001pubmed:authorpubmed-author:MoossaA RARlld:pubmed
pubmed-article:7622001pubmed:authorpubmed-author:MilesP DPDlld:pubmed
pubmed-article:7622001pubmed:authorpubmed-author:OlefskyJ MJMlld:pubmed
pubmed-article:7622001pubmed:authorpubmed-author:ReichartDDlld:pubmed
pubmed-article:7622001pubmed:authorpubmed-author:KhoursheedMMlld:pubmed
pubmed-article:7622001pubmed:authorpubmed-author:LevisettiMMlld:pubmed
pubmed-article:7622001pubmed:issnTypePrintlld:pubmed
pubmed-article:7622001pubmed:volume44lld:pubmed
pubmed-article:7622001pubmed:ownerNLMlld:pubmed
pubmed-article:7622001pubmed:authorsCompleteYlld:pubmed
pubmed-article:7622001pubmed:pagination947-53lld:pubmed
pubmed-article:7622001pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:7622001pubmed:meshHeadingpubmed-meshheading:7622001-...lld:pubmed
pubmed-article:7622001pubmed:meshHeadingpubmed-meshheading:7622001-...lld:pubmed
pubmed-article:7622001pubmed:meshHeadingpubmed-meshheading:7622001-...lld:pubmed
pubmed-article:7622001pubmed:meshHeadingpubmed-meshheading:7622001-...lld:pubmed
pubmed-article:7622001pubmed:meshHeadingpubmed-meshheading:7622001-...lld:pubmed
pubmed-article:7622001pubmed:meshHeadingpubmed-meshheading:7622001-...lld:pubmed
pubmed-article:7622001pubmed:meshHeadingpubmed-meshheading:7622001-...lld:pubmed
pubmed-article:7622001pubmed:meshHeadingpubmed-meshheading:7622001-...lld:pubmed
pubmed-article:7622001pubmed:meshHeadingpubmed-meshheading:7622001-...lld:pubmed
pubmed-article:7622001pubmed:meshHeadingpubmed-meshheading:7622001-...lld:pubmed
pubmed-article:7622001pubmed:meshHeadingpubmed-meshheading:7622001-...lld:pubmed
pubmed-article:7622001pubmed:meshHeadingpubmed-meshheading:7622001-...lld:pubmed
pubmed-article:7622001pubmed:meshHeadingpubmed-meshheading:7622001-...lld:pubmed
pubmed-article:7622001pubmed:year1995lld:pubmed
pubmed-article:7622001pubmed:articleTitleKinetics of insulin action in vivo. Identification of rate-limiting steps.lld:pubmed
pubmed-article:7622001pubmed:affiliationDepartment of Surgery, University of California, San Diego, USA.lld:pubmed
pubmed-article:7622001pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7622001pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:7622001pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7622001lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7622001lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7622001lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7622001lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7622001lld:pubmed